Salivary gland genetic vaccination: a scalable technology for promoting distal mucosal immunity and heightened systemic immune responses
Vaccine, ISSN: 0264-410X, Vol: 22, Issue: 19, Page: 2500-2504
2004
- 11Citations
- 10Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- 11
- CrossRef10
- Captures10
- Readers10
- 10
Article Description
Use of plasmid DNA for vaccination has been demonstrated quite successfully in small rodents. However, some of the many challenges of DNA vaccine development are the relatively low performance obtained in larger animals and a generally weak mucosal immune response. Vaccination through salivary gland (SG) cannulation and delivery of aqueous solutions of DNA is one potential solution. The scalability of SG DNA vaccination was tested in multiple animal models; antigen specific titers above 10,000 were demonstrated in dogs and rats. Immune responses were also present at a variety of mucosal sites. In conclusion, our data demonstrate that DNA vaccination to the SG presents a unique and advantageous method for eliciting systemic and mucosal immune responses.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X04002622; http://dx.doi.org/10.1016/j.vaccine.2003.12.034; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=2942590446&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/15193415; https://linkinghub.elsevier.com/retrieve/pii/S0264410X04002622; https://dx.doi.org/10.1016/j.vaccine.2003.12.034
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know